Voya Investment Management LLC Decreases Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Voya Investment Management LLC cut its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 18.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,960 shares of the company’s stock after selling 10,557 shares during the quarter. Voya Investment Management LLC owned 0.10% of Apogee Therapeutics worth $2,082,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Alliancebernstein L.P. grew its stake in shares of Apogee Therapeutics by 13.5% in the 4th quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company’s stock worth $61,390,000 after buying an additional 160,822 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Apogee Therapeutics by 38.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,052,595 shares of the company’s stock worth $47,683,000 after acquiring an additional 294,514 shares in the last quarter. Affinity Asset Advisors LLC increased its stake in Apogee Therapeutics by 40.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 931,728 shares of the company’s stock worth $42,207,000 after acquiring an additional 267,530 shares during the last quarter. Franklin Resources Inc. raised its position in Apogee Therapeutics by 0.6% during the fourth quarter. Franklin Resources Inc. now owns 866,188 shares of the company’s stock valued at $39,238,000 after purchasing an additional 5,199 shares during the period. Finally, Barclays PLC lifted its stake in shares of Apogee Therapeutics by 30.6% in the 4th quarter. Barclays PLC now owns 476,760 shares of the company’s stock valued at $21,597,000 after purchasing an additional 111,714 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on APGE shares. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Wedbush reissued an “outperform” rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Finally, Citigroup began coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $95.00 price target for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics has a consensus rating of “Buy” and an average price target of $92.17.

Apogee Therapeutics Stock Up 2.3 %

APGE stock opened at $40.12 on Friday. Apogee Therapeutics, Inc. has a twelve month low of $26.20 and a twelve month high of $63.50. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -16.58 and a beta of 1.70. The business’s fifty day simple moving average is $35.65 and its two-hundred day simple moving average is $42.14.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). Research analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Insiders Place Their Bets

In related news, insider Carl Dambkowski sold 3,520 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total value of $143,228.80. Following the completion of the sale, the insider now directly owns 252,623 shares of the company’s stock, valued at $10,279,229.87. This represents a 1.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the transaction, the chief executive officer now directly owns 1,292,987 shares in the company, valued at $38,983,558.05. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,970 shares of company stock worth $1,241,701 in the last three months. Corporate insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.